Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48

Article  PubMed  Google Scholar 

American Cancer Society (2023) Facts & figures 2023. In: Key statistics for pancreatic cancer. American Cancer Society, Atlanta, GA

DePeralta DK, Ogami T, Zhou JM, Schell MJ, Powers BD, Hodul PJ, Malafa MP, Fleming JB (2020) Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB (Oxford) 22:241–248

Article  PubMed  Google Scholar 

Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR (2020) Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 70:375–403

Article  PubMed  PubMed Central  Google Scholar 

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081

Article  CAS  PubMed  Google Scholar 

Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O’Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW, Cancer ESGfP, (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (2023) Pancreatic Adenocarcinoma (V2.2023)

Sugawara T, Rodriguez Franco S, Sherman S, Kirsch MJ, Colborn K, Ishida J, Grandi S, Al-Musawi MH, Gleisner A, Schulick RD, Del Chiaro M (2023) Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol 9:316–323

Article  PubMed  Google Scholar 

Aloia TA, Zimmitti G, Conrad C, Gottumukalla V, Kopetz S, Vauthey JN (2014) Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol 110:107–114

Article  PubMed  PubMed Central  Google Scholar 

Bilimoria KY, Bentrem DJ, Lillemoe KD, Talamonti MS, Ko CY, Pancreatic Cancer Quality Indicator Development Expert Panel AeCoS (2009) Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst 101:848–859

Article  Google Scholar 

Simons JP, Shah SA, Ng SC, Whalen GF, Tseng JF (2009) National complication rates after pancreatectomy: beyond mere mortality. J Gastrointest Surg 13:1798–1805

Article  PubMed  Google Scholar 

Kneuertz PJ, Pitt HA, Bilimoria KY, Smiley JP, Cohen ME, Ko CY, Pawlik TM (2012) Risk of morbidity and mortality following hepato-pancreato-biliary surgery. J Gastrointest Surg 16:1727–1735

Article  PubMed  Google Scholar 

Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, Ko CY, Bentrem DJ (2014) Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 260:372–377

Article  PubMed  Google Scholar 

Kim BJ, Caudle AS, Gottumukkala V, Aloia TA (2016) The impact of postoperative complications on a timely return to intended oncologic therapy (RIOT): the role of enhanced recovery in the cancer journey. Int Anesthesiol Clin 54:e33-46

Article  PubMed  Google Scholar 

Zhang J, Wu WM, You L, Zhao YP (2013) Robotic versus open pancreatectomy: a systematic review and meta-analysis. Ann Surg Oncol 20:1774–1780

Article  PubMed  Google Scholar 

Mantzavinou A, Uppara M, Chan J, Patel B (2022) Robotic versus open pancreaticoduodenectomy, comparing therapeutic indexes; a systematic review. Int J Surg 101:106633

Article  PubMed  Google Scholar 

de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, de Hingh I, Kazemier G, Klaase J, de Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M, Group DPC (2019) Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg 269:2–9

Article  Google Scholar 

Liu Q, Li M, Gao Y, Jiang T, Han B, Zhao G, Lin C, Lau WY, Zhao Z, Liu R (2024) Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 9:428–437

Article  PubMed  Google Scholar 

Korrel M, Jones LR, van Hilst J, Balzano G, Björnsson B, Boggi U, Bratlie SO, Busch OR, Butturini G, Capretti G, Casadei R, Edwin B, Emmen AMLH, Esposito A, Falconi M, Groot Koerkamp B, Keck T, de Kleine RHJ, Kleive DB, Kokkola A, Lips DJ, Lof S, Luyer MDP, Manzoni A, Marudanayagam R, de Pastena M, Pecorelli N, Primrose JN, Ricci C, Salvia R, Sandström P, Vissers FLIM, Wellner UF, Zerbi A, Dijkgraaf MGW, Besselink MG, Abu Hilal M, (E-MIPS) ECoMIPS, (2023) Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Lancet Reg Health Eur 31:100673

Article  PubMed  PubMed Central  Google Scholar 

Wang M, Pan S, Qin T, Xu X, Huang X, Liu J, Chen X, Zhao W, Li J, Liu C, Li D, Liu Y, Zhou B, Zhu F, Ji S, Cheng H, Li Z, Tang Y, Peng X, Yu G, Chen W, Ma H, Xiong Y, Meng L, Lu P, Zhang Z, Yu X, Zhang H, Qin R (2023) Short-term outcomes following laparoscopic vs open pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma: a randomized clinical trial. JAMA Surg 158:1245–1253

Article  PubMed  Google Scholar 

Fung G, Sha M, Kunduzi B, Froghi F, Rehman S, Froghi S (2022) Learning curves in minimally invasive pancreatic surgery: a systematic review. Langenbecks Arch Surg 407:2217–2232

Article  PubMed  PubMed Central  Google Scholar 

Naffouje SA, Kamarajah SK, Denbo JW, Salti GI, Dahdaleh FS (2022) Surgical approach does not affect return to intended oncologic therapy following pancreaticoduodenectomy for pancreatic adenocarcinoma: a propensity-matched study. Ann Surg Oncol 29:7793–7803

Article  PubMed  Google Scholar 

Mickel TA, Kutlu OC, Silberfein EJ, Hsu C, Chai CY, Fisher WE, Van Buren G, Camp ER (2022) Factors associated with inability to return to intended oncologic treatment in pancreatic cancer. Am J Surg 224:635–640

Article  PubMed  Google Scholar 

Witt RG, Hirata Y, Prakash LR, Newhook TE, Maxwell JE, Kim MP, Tran Cao HS, Lee JE, Vauthey JN, Katz MHG, Tzeng CD, Ikoma N (2023) Comparative analysis of opioid use between robotic and open pancreatoduodenectomy. J Hepatobiliary Pancreat Sci 30:523–531

Article  PubMed  Google Scholar 

Ikoma N, Kim MP, Tran Cao HS, Prakash LP, Maxwell JE, Tzeng CD, Mansfield PF, Lee JE, Badgwell BD, Katz MHG (2022) Early experience of a robotic foregut surgery program at a cancer center: video of shared steps in robotic pancreatoduodenectomy and gastrectomy. Ann Surg Oncol 29:285

Article  PubMed  Google Scholar 

Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MHG (2017) Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 35:2324–2328

Article  CAS  PubMed  Google Scholar 

Strasberg SM, Linehan DC, Hawkins WG (2009) The accordion severity grading system of surgical complications. Ann Surg 250:177–186

Article  PubMed  Google Scholar 

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G, Group DPC (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial. J Clin Oncol 38:1763–1773

Article  PubMed  PubMed Central  Google Scholar 

Xia BT, Ahmad SA, Al Humaidi AH, Hanseman DJ, Ethun CG, Maithel SK, Kooby DA, Salem A, Cho CS, Weber SM, Stocker SJ, Talamonti MS, Bentrem DJ, Abbott DE (2017) Time to initiation of adjuvant chemotherapy in pancreas cancer: a multi-institutional experience. Ann Surg Oncol 24:2770–2776

Article  PubMed  Google Scholar 

Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK (2019) Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer. JAMA Netw Open 2:e199126

Article  PubMed  PubMed Central  Google Scholar 

Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O’Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthoney A, Sumpter K, Carter R, Büchler MW (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512

Article  PubMed  Google Scholar 

Lillemoe HA, Marcus RK, Kim BJ, Narula N, Davis CH, Aloia TA (2019) Detours on the road to recovery: what factors delay readiness to return to intended oncologic therapy (RIOT) after liver resection for malignancy? J Gastrointest Surg 23:2362–2371